Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLYM NASDAQ:EQ NASDAQ:RLMD NASDAQ:ZSQR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLYMClimb Bio$13.08+3.3%$10.82$1.18▼$13.46$749M0.091.59 million shs6.32 million shsEQEquillium$3.02+2.4%$2.49$0.29▼$3.45$192.84M1.771.02 million shs417,384 shsRLMDRelmada Therapeutics$6.69+3.7%$6.93$0.55▼$8.00$701.72M0.392.29 million shs15.61 million shsZSQRCoeptis Therapeutics$12.46+2.1%$12.37$7.21▼$21.41$640.84M-0.22701,029 shs5.69 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLYMClimb Bio0.00%+14.24%+15.34%+86.32%+906.15%EQEquillium0.00%-0.95%+6.37%+60.69%+805.03%RLMDRelmada Therapeutics0.00%-0.59%-7.72%+4.04%+1,138.89%ZSQRCoeptis Therapeutics0.00%-25.52%+39.84%+16.67%+51.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLYMClimb Bio$13.08+3.3%$10.82$1.18▼$13.46$749M0.091.59 million shs6.32 million shsEQEquillium$3.02+2.4%$2.49$0.29▼$3.45$192.84M1.771.02 million shs417,384 shsRLMDRelmada Therapeutics$6.69+3.7%$6.93$0.55▼$8.00$701.72M0.392.29 million shs15.61 million shsZSQRCoeptis Therapeutics$12.46+2.1%$12.37$7.21▼$21.41$640.84M-0.22701,029 shs5.69 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLYMClimb Bio0.00%+14.24%+15.34%+86.32%+906.15%EQEquillium0.00%-0.95%+6.37%+60.69%+805.03%RLMDRelmada Therapeutics0.00%-0.59%-7.72%+4.04%+1,138.89%ZSQRCoeptis Therapeutics0.00%-25.52%+39.84%+16.67%+51.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLYMClimb Bio 3.07Buy$21.7366.11% UpsideEQEquillium 2.78Moderate Buy$7.57150.63% UpsideRLMDRelmada Therapeutics 2.75Moderate Buy$12.0079.37% UpsideZSQRCoeptis Therapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest EQ, RLMD, CLYM, and ZSQR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026EQEquillium Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026CLYMClimb Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.006/18/2026RLMDRelmada Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/18/2026RLMDRelmada Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/18/2026RLMDRelmada Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/12/2026CLYMClimb Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$17.006/11/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $20.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.005/28/2026EQEquillium Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$7.00(Data available from 6/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLYMClimb BioN/AN/AN/AN/A$3.36 per shareN/AEQEquillium$41.10M4.65N/AN/A$0.47 per share6.43RLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/AZSQRCoeptis Therapeutics$1.36M471.19N/AN/A$2.63 per share4.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLYMClimb Bio-$59.85M-$0.78N/AN/AN/AN/A-31.45%-30.39%8/11/2026 (Estimated)EQEquillium-$22.40M-$0.32N/AN/AN/AN/A-61.43%-53.72%8/13/2026 (Estimated)RLMDRelmada Therapeutics-$57.38M-$1.09N/AN/AN/AN/A-71.22%-64.46%8/6/2026 (Estimated)ZSQRCoeptis Therapeutics-$11.92M-$2.52N/AN/AN/A-810.04%-92.29%-73.52%N/ALatest EQ, RLMD, CLYM, and ZSQR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ZSQRCoeptis TherapeuticsN/A-$0.65N/A-$0.65N/A$0.11 million5/13/2026Q1 2026EQEquillium-$0.04-$0.06-$0.02-$0.06N/AN/A5/12/2026Q1 2026RLMDRelmada Therapeutics-$0.18-$0.22-$0.04-$0.22N/AN/A5/7/2026Q1 2026CLYMClimb Bio-$0.26-$0.20+$0.06-$0.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLYMClimb BioN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/AZSQRCoeptis TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLYMClimb BioN/A27.8627.86EQEquilliumN/A18.6218.62RLMDRelmada TherapeuticsN/A18.2518.25ZSQRCoeptis Therapeutics0.013.253.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLYMClimb Bio69.76%EQEquillium27.05%RLMDRelmada Therapeutics45.24%ZSQRCoeptis Therapeutics13.88%Insider OwnershipCompanyInsider OwnershipCLYMClimb Bio2.60%EQEquillium17.84%RLMDRelmada Therapeutics14.50%ZSQRCoeptis Therapeutics24.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLYMClimb Bio957.26 million55.77 millionN/AEQEquillium4063.23 million51.95 millionNot OptionableRLMDRelmada Therapeutics10104.89 million89.68 millionOptionableZSQRCoeptis Therapeutics251.43 million38.96 millionNot OptionableEQ, RLMD, CLYM, and ZSQR HeadlinesRecent News About These CompaniesZ Squared, Inc. to Acquire Majority Interest in Paradox Data and Its Union County Campus, a Next-Generation Data Center Development Targeting Up to 150 MW of Firm PowerJune 25 at 7:00 AM | prnewswire.comZ Squared to Participate in Maxim Group's AI Data Center SummitJune 9, 2026 | prnewswire.comZ Squared, Inc. Enters $50 Million Committed Equity Forward Purchase Agreement to Support AI Infrastructure BuildoutJune 4, 2026 | prnewswire.comZ Squared, Inc. Announces Preliminary Inclusion in Russell 3000® and Russell 2000® IndexesMay 27, 2026 | prnewswire.comVanderbilt Report: Z Squared Locks In Zero-Cash, Zero-Debt Path to 42 MW of AI-Ready PowerMay 26, 2026 | globenewswire.comZ Squared, Inc. Outlines Phase 1 Plan to Reach 100 MW of AI-Ready Infrastructure for Inference WorkloadsMay 19, 2026 | prnewswire.comZ Squared Appoints Jon Najarian, Pete Najarian, Marc LoPresti and Jay Zapata to Newly Formed Advisory BoardMay 4, 2026 | prnewswire.comZ Squared to Acquire Skycore Digital, Adding 24 MW of Energized AI Infrastructure with Expansion Path to 42 MWApril 29, 2026 | prnewswire.comZ Squared, Inc. to Ring the Nasdaq Closing Bell in Celebration of Its Listing on the Nasdaq Global MarketApril 28, 2026 | prnewswire.comCoeptis Therapeutics Announces Approval of Z Squared Inc.'s Nasdaq Listing ApplicationApril 27, 2026 | finanznachrichten.deZ Squared Provides Additional Information on Previously Disclosed Pro Rata DistributionApril 27, 2026 | tmcnet.comCoeptis Therapeutics Receives Shareholder Approval Towards Z Squared MergerApril 27, 2026 | finanznachrichten.deZ Squared Inc.: Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global MarketApril 25, 2026 | finanznachrichten.deZ Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global MarketApril 24, 2026 | prnewswire.comCoeptis Therapeutics: Coeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing ApplicationApril 9, 2026 | finanznachrichten.deWhy Coeptis Therapeutics Holdings, Inc.’s (COEP) Stock Is Up 10.60%April 9, 2026 | aaii.comACoeptis Announces Approval of Z Squared Inc.’s Nasdaq Listing ApplicationApril 7, 2026 | markets.businessinsider.comNasdaq Approves Listing for Coeptis Therapeutics Holdings, Inc. Post-Merger with Z Squared Inc.April 7, 2026 | quiverquant.comQCoeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing ApplicationApril 7, 2026 | globenewswire.comCoeptis Therapeutics: Vanderbilt Report: Coeptis / Z Squared Merger Enters Final Stretch - Closing Imminent as Institutional Tailwinds BuildMarch 9, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesDraining the Tank: Big Oil Runs on FumesBy Jeffrey Neal Johnson | June 17, 20263 ETFs Giving Ready-Made Access to the Discounted International Small-Cap SpaceBy Nathan Reiff | June 14, 2026Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence?By Ryan Hasson | June 2, 2026Robinhood Wants a Bigger Role in IPOs—Here's Why It MattersBy Leo Miller | June 14, 2026Coke's $10B India IPO Plan Pops the Top on Hidden ValueBy Jeffrey Neal Johnson | June 3, 2026EQ, RLMD, CLYM, and ZSQR Company DescriptionsClimb Bio NASDAQ:CLYM$13.08 +0.42 (+3.32%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$13.12 +0.04 (+0.31%) As of 06/26/2026 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.Equillium NASDAQ:EQ$3.02 +0.07 (+2.41%) Closing price 06/26/2026 03:59 PM EasternExtended Trading$2.98 -0.05 (-1.52%) As of 06/26/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Relmada Therapeutics NASDAQ:RLMD$6.69 +0.24 (+3.72%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$6.68 -0.01 (-0.07%) As of 06/26/2026 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.Coeptis Therapeutics NASDAQ:ZSQR$12.46 +0.26 (+2.13%) As of 06/26/2026 04:00 PM EasternCoeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
